Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome

Paul P. Dobesh, Toby C. Trujillo

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


There are currently over 1 million patients admitted to hospitals in the United States with the diagnosis of non-ST-segment elevation acute coronary syndrome (NSTE ACS). Due to the significant morbidity and mortality associated with NSTE ACS, appropriate use of the numerous medications employed is critical in ensuring optimal outcomes. Because atherosclerotic plaque rupture and thrombus formation are the central pathophysiologic process in patients with NSTE ACS, it is important to utilize effective and safe combinations of antiplatelet and anticoagulant drug therapy. There are a number of different anticoagulant agents available for use in patients with NSTE ACS, but it is essential to have an in-depth knowledge of the setting in which these agents have been investigated, what current consensus guidelines recommend, as well as an appreciation for the treatment approach and philosophy of the institution for management of patients with NSTE ACS. In this review manuscript, the reader will find an evaluation of the current guidelines concerning the use of anticoagulant therapy in patients with NSTE ACS, as well as a detailed examination of the literature with critical analysis on issues that should be considered when deciding on the appropriate implementation of anticoagulant therapy in protocols for NSTE ACS patients.

Original languageEnglish (US)
Pages (from-to)324-334
Number of pages11
JournalJournal of Pharmacy Practice
Issue number4
StatePublished - Aug 2010


  • acute coronary syndrome
  • anticoagulation
  • bivalirudin
  • cardiology
  • coronary artery disease
  • enoxaparin
  • fondaparinux
  • low-molecular-weight heparin
  • unfractionated heparin

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome'. Together they form a unique fingerprint.

Cite this